ROR1 and triple-negative breast carcinoma: Surprisingly, the ROR1 mRNA was highly expressed in HER2+ and triple-negative breast cancer (TNBC) tumors primarily in those patients who had a progressive, stable, or partial response to treatment (Fig. 5A).